GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » DarioHealth Corp (NAS:DRIO) » Definitions » Sloan Ratio %

DarioHealth (DarioHealth) Sloan Ratio % : -29.57% (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is DarioHealth Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

DarioHealth's Sloan Ratio for the quarter that ended in Dec. 2023 was -29.57%.

Warning Sign:

When sloan ratio (-29.57)% higher than 25% or lower than -25%, earnings are more likely to be made up of accruals.

As of Dec. 2023, DarioHealth has a Sloan Ratio of -29.57%, indicating earnings are more likely to be made up of accruals.


DarioHealth Sloan Ratio % Historical Data

The historical data trend for DarioHealth's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DarioHealth Sloan Ratio % Chart

DarioHealth Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Sloan Ratio %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.73 -28.49 -18.08 -11.56 -29.57

DarioHealth Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Sloan Ratio % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -11.56 -18.37 -20.67 -24.65 -29.57

Competitive Comparison of DarioHealth's Sloan Ratio %

For the Health Information Services subindustry, DarioHealth's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DarioHealth's Sloan Ratio % Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, DarioHealth's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where DarioHealth's Sloan Ratio % falls into.



DarioHealth Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

DarioHealth's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (A: Dec. 2023 )-Cash Flow from Operations (A: Dec. 2023 )
-Cash Flow from Investing (A: Dec. 2023 ))/Total Assets (A: Dec. 2023 )
=(-59.427--30.379
--0.547)/96.389
=-29.57%

DarioHealth's Sloan Ratio for the quarter that ended in Dec. 2023 is calculated as

Sloan Ratio=(Net Income (TTM)-Cash Flow from Operations (TTM))
-Cash Flow from Investing (TTM))/Total Assets (Q: Dec. 2023 )
=(-59.427--30.379
--0.547)/96.389
=-29.57%

DarioHealth's Net Income for the trailing twelve months (TTM) ended in Dec. 2023 was -12.825 (Mar. 2023 ) + -16.585 (Jun. 2023 ) + -15.732 (Sep. 2023 ) + -14.285 (Dec. 2023 ) = $-59.43 Mil.
DarioHealth's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 was -4.757 (Mar. 2023 ) + -9.636 (Jun. 2023 ) + -8.645 (Sep. 2023 ) + -7.341 (Dec. 2023 ) = $-30.38 Mil.
DarioHealth's Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 was -4.362 (Mar. 2023 ) + 4.179 (Jun. 2023 ) + -0.281 (Sep. 2023 ) + -0.083 (Dec. 2023 ) = $-0.55 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


DarioHealth  (NAS:DRIO) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Dec. 2023, DarioHealth has a Sloan Ratio of -29.57%, indicating earnings are more likely to be made up of accruals.


DarioHealth Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of DarioHealth's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.


DarioHealth (DarioHealth) Business Description

Traded in Other Exchanges
N/A
Address
18 W. 18th Street, New York, NY, USA, 10011
DarioHealth Corp is a digital health company. It offers user-centric a multi-chronic condition digital therapeutics platform that delivers personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. DarioHealth serves customers globally.
Executives
Jon H. Kaplan director 1573 MALLORY LANE, SUITE 100, BRENTWOOD TN 37027
Erez Raphael director, officer: Chief Executive Officer 9 HALAMISH STREET, CAESAREA INDUSTRIAL PARK, CAESAREA L3 38900
Dennis M Mcgrath director C/O PAVMED INC., ONE GRAND CENTRAL PLACE, STE. 4600, NEW YORK NY 10165
Dror Bacher officer: Chief Operating Officer 9 HALAMISH STREET, CAESAREA INDUSTRIAL PARK L3 3088900
Oded Cohen officer: GM MSK 8 HATOKHEN ST., CAESAREA INDUSTRIAL PARK L3 3088900
Adam K Stern director STERN AEGIS VENTURES, 810 7TH AVENUE 22ND FLOOR, NEW YORK NY 10019
Dennis Matheis director 8 HATOKHEN ST., CAESAREA L3 38900
Yoav Shaked director 8 HATOKHEN ST., CAESAREA L3 3088900
Yadin Shemmer director 8 HATOKHEN ST., CAESAREA L3 3088900
Richard Allan Anderson officer: President, GM of North America C/O DARIOHEALTH CORP., 18 W. 18TH ST, 5TH FLOOR, NEW YORK NY 10011
Yalon Farhi director C/O LABSTYLE INNOVATIONS CORP., 9 HALAMISH ST., CAESAREA INDUSTRIAL PARK, CAESAREA L3 3088900
Hila Karah director 9 HALAMISH STREET, CAESAREA INDUSTRIAL PARK, CAESAREA L3 38900
Zvi Ben-david officer: Chief Financial Officer 9 HALAMISH STREET, CAESAREA INDUSTRIAL PARK, CAESAREA L3 38900
Glen Moller director 8 HATOKHEN ST., CAESAREA L3 3088900
Olivier Roger Jarry officer: See Remarks 15 ROCKRIDGE RD, LARCHMONT NY 10538-3918